It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Genetically complex ocular neuropathies, such as glaucoma, are a major cause of visual impairment worldwide. There is a growing need to generate suitable human representative in vitro and in vivo models, as there is no effective treatment available once damage has occured. Retinal organoids are increasingly being used for experimental gene therapy, stem cell replacement therapy and small molecule therapy. There are multiple protocols for the development of retinal organoids available, however, one potential drawback of the current methods is that the organoids can take between 6 weeks and 12 months on average to develop and mature, depending on the specific cell type wanted. Here, we describe and characterise a protocol focused on the generation of retinal ganglion cells within an accelerated four week timeframe without any external small molecules or growth factors. Subsequent long term cultures yield fully differentiated organoids displaying all major retinal cell types. RPE, Horizontal, Amacrine and Photoreceptors cells were generated using external factors to maintain lamination.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Amsterdam UMC, University of Amsterdam (UvA), Department of Clinical Genetics, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262)
2 University of Groningen, University Medical Center Groningen, Department of Ophthalmology, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598)
3 Amsterdam UMC, University of Amsterdam (UvA), Department of Clinical Genetics, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262); Amsterdam UMC, University of Amsterdam (UvA), Department of Ophthalmology, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262); Netherlands Institute for Neuroscience (NIN-KNAW), Amsterdam, The Netherlands (GRID:grid.419918.c) (ISNI:0000 0001 2171 8263)